Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Clin Cancer Res. 2015 Feb 17;21(13):2952–2962. doi: 10.1158/1078-0432.CCR-14-2998

Figure 2. Co-expression of CD40L and OX40L by K562-derived whole-cell vaccine maximizes the stimulation of CMV-CTLs in vivo.

Figure 2

Panel A. Schematic representation of the xenograft mouse model in NOG/SCID/γc−/− mice. Panel B. Engraftment of human CD45+ cells in the spleen, 14 days after vaccination. Panel C. Phenotypic analysis of human CD45+ cells engrafted in the spleen by day 14. Data represent mean ± SD of 8 mice per group. Panel D. Enumeration of the CMV-CTLs in isolated human CD45+ cells as assessed by IFNγ ELISpot in response to CMV-pp65 and irrelevant pepmixes. Data represent mean ± SD of 8 mice per group.